JP2008527038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008527038A5 JP2008527038A5 JP2007552192A JP2007552192A JP2008527038A5 JP 2008527038 A5 JP2008527038 A5 JP 2008527038A5 JP 2007552192 A JP2007552192 A JP 2007552192A JP 2007552192 A JP2007552192 A JP 2007552192A JP 2008527038 A5 JP2008527038 A5 JP 2008527038A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- -1 3-amino-2- (R, S) -fluoropropyl Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000000394 mitotic Effects 0.000 claims 4
- 230000000051 modifying Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000005275 alkylenearyl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000004429 atoms Chemical group 0.000 claims 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 230000020347 spindle assembly Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 208000007502 Anemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000005017 Glioblastoma Diseases 0.000 claims 2
- 208000009285 Lymphoma, Large B-Cell, Diffuse Diseases 0.000 claims 2
- 208000004235 Neutropenia Diseases 0.000 claims 2
- 108010015181 PPAR delta Proteins 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102100003648 PPARD Human genes 0.000 claims 2
- 102100000077 PPARG Human genes 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims 2
- 230000003474 anti-emetic Effects 0.000 claims 2
- 230000001028 anti-proliferant Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 102000027730 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008001 retinoid hormone receptors Proteins 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100000541 MARK2 Human genes 0.000 claims 1
- 101700064507 MARK2 Proteins 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 125000004946 alkenylalkyl group Chemical group 0.000 claims 1
- 125000005038 alkynylalkyl group Chemical group 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 230000001672 cytoproliferative Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000007275 lymphatic system cancer Diseases 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64493305P | 2005-01-19 | 2005-01-19 | |
PCT/US2006/001364 WO2006078574A2 (en) | 2005-01-19 | 2006-01-13 | Mitotic kinesin inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008527038A JP2008527038A (ja) | 2008-07-24 |
JP2008527038A5 true JP2008527038A5 (US07794700-20100914-C00152.png) | 2009-03-05 |
JP4545196B2 JP4545196B2 (ja) | 2010-09-15 |
Family
ID=36692758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007552192A Expired - Fee Related JP4545196B2 (ja) | 2005-01-19 | 2006-01-13 | 有糸分裂キネシン阻害剤 |
Country Status (7)
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
US20130331294A1 (en) | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
KR101735868B1 (ko) | 2010-02-17 | 2017-05-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소고리 화합물 |
EA201201404A1 (ru) * | 2010-04-15 | 2013-04-30 | Новартис Аг | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
CN103153970A (zh) * | 2010-04-15 | 2013-06-12 | 诺瓦提斯公司 | 作为ksp抑制剂的*唑和噻唑化合物 |
EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
EP3512858B1 (en) * | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Fused bicyclic inhibitors of menin-mll interaction |
US10745409B2 (en) | 2016-12-15 | 2020-08-18 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
CA3164153A1 (en) * | 2019-12-18 | 2021-06-24 | Universite De Montreal | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02004162A (es) * | 1999-10-27 | 2003-08-20 | Cytokinetics Inc | Metodo y composiciones que utilizan quinazolinonas. |
EP1465896A4 (en) * | 2001-12-06 | 2006-01-11 | Merck & Co Inc | MITOTIC INHIBITORS OF KINESIN |
WO2003049678A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
EP1481077B1 (en) * | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
JP4597519B2 (ja) * | 2001-12-06 | 2010-12-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害薬 |
EP1551962A4 (en) * | 2002-07-08 | 2007-08-01 | Merck & Co Inc | MITOTIC KINESIN BINDING CENTER |
JP2006515886A (ja) * | 2003-01-17 | 2006-06-08 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
CA2518224C (en) * | 2003-03-07 | 2010-06-15 | Astrazeneca Ab | Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof |
-
2006
- 2006-01-13 US US11/795,440 patent/US20080102068A1/en not_active Abandoned
- 2006-01-13 JP JP2007552192A patent/JP4545196B2/ja not_active Expired - Fee Related
- 2006-01-13 CN CNA2006800025407A patent/CN101107253A/zh active Pending
- 2006-01-13 EP EP06718441A patent/EP1856128A4/en not_active Withdrawn
- 2006-01-13 AU AU2006206738A patent/AU2006206738A1/en not_active Abandoned
- 2006-01-13 WO PCT/US2006/001364 patent/WO2006078574A2/en active Application Filing
- 2006-01-13 CA CA002595127A patent/CA2595127A1/en not_active Abandoned